News

About 2.5 years of treatment with tolebrutinib was associated with low relapse rates and stable disability levels among people with relapsing forms of multiple sclerosis (MS), according to data in an ongoing, open-label extension of a Phase 2b trial. The oral treatment also continued to show a “favorable”…

Supplements with tauroursodeoxycholic acid (TUDCA) were generally well tolerated among people with progressive forms of multiple sclerosis (MS), according to findings from a small clinical trial. Results also showed that patients given TUDCA supplements had lower levels of certain inflammatory immune cells than those given a placebo, but no…

Use of the cell therapy MSC-NP failed to show a significant effect on overall disability scores among people with progressive forms of multiple sclerosis (MS), according to data from a Phase 2 clinical trial. Results, however, indicated that MSC-NP improved walking ability for people with more advanced disease —…

Damage to the myelin sheath, a hallmark feature of multiple sclerosis (MS), leads to increased levels of fatty molecules called VLCFAs, which are converted by brain cells into an inflammation-driving signaling molecule called S1P, a study suggests. The discovery of this novel molecular pathway may open up new avenues…

Tokachi, a region in northern Japan, has seen a steady increase in the prevalence or proportion of people in the population living with multiple sclerosis (MS) over the past two decades, a recent study found. Data show the disease has also become more common in women in northern…

Most treatments for multiple sclerosis (MS) are not associated with an increased risk of complications during pregnancy, according to a new analysis. A few therapies were associated with slightly elevated rates of congenital abnormalities for babies exposed to treatment during pregnancy, but small sample sizes limit being able to…

People with secondary progressive multiple sclerosis (SPMS) seem to experience slower worsening of their disabilities than those with the primary progressive form of the disease (PPMS), a new study reports. However, SPMS patients tend to be older and have more advanced disability when they enter the progressive stage…

Owen Mumford‘s Aidaptus auto-injector, which lets a wide range of under-the-skin medications to be administered, has won a Red Dot Award in the Product Design 2023 category. Launched in 2021, Aidaptus is a disposable auto-injector whose design fits multiple-sized prefilled glass syringes without changing parts. This could provide…

The first participant has completed dosing in a Phase 1 clinical trial testing FSD Pharma‘s Lucid-21-302, an experimental oral medication for all types of multiple sclerosis (MS), in healthy volunteers. After receiving a green light from Health Canada to launch the first-in-human trial, the company began by…

Sensoria Health and Padula Rehabilitation Technologies (PRT) have launched a wearable system crafted for optometry practices to improve balance, gait, and coordination, and to help reduce the risk of falls, particularly among older people. The system, NeurOpTrek powered by Sensoria, is designed to assess a person’s fall risk…

Multiple sclerosis (MS) patients with greater psychological resilience — a better ability to cope with and recover quickly from problems and difficulties — tend to have higher levels of social and occupational functioning, a new study found. Resilience was linked to a number of functions, including relationships, communication, social…

Pipeline Therapeutics is collaborating with a branch of Janssen Pharmaceuticals to advance PIPE-307, a potential oral treatment of nervous system conditions that is expected to enter a clinical trial in people with relapsing-remitting multiple sclerosis (RRMS). The compound previously was found to be safe and tolerable in…

A novel formulation of ibudilast, delivered into the nose, was able to reduce inflammation and prevent nerve damage in a mouse model of multiple sclerosis (MS), a study found. The nasal formulation also improved regeneration of myelin, the protective sheath around nerve fibers that is progressively lost…

A high-dose vitamin D supplement did not reduce the risk of relapses in people with relapsing-remitting multiple sclerosis (RRMS) already using a disease-modifying therapy to control disease activity, according to findings of a Phase 3 clinical trial. The VIDAMS study (NCT01490502) — standing for Vitamin D…

A three-month yoga program was significantly better than physical therapy at improving quality of life in people with multiple sclerosis (MS), a Russian study reports. Significant effects were observed in patients’ physical and social functioning, life activity, and mental health, researchers found. “Regular yoga classes under the guidance of…

Scientists have developed new skin patches that could offer a more convenient and less painful way to administer antibody-based medicines to people with multiple sclerosis (MS) and other disorders. “The developed [skin] patch is minimally invasive, self-administrable, and designed to be fully embedded into the skin with a short…

Abnormal perceptions of discomfort and fatigue likely play a role in causing increased heat and cold sensitivity to extreme temperatures among people with multiple sclerosis (MS), a new study shows. However, the results suggest that MS does not generally affect how the body regulates its own temperature. “Our findings…

People with multiple sclerosis (MS) tend to accrue more medical costs after switching to infusible therapies Ocrevus (ocrelizumab), Tysabri (natalizumab), or Lemtrada (alemtuzumab), according to an analysis of data from commercially insured patients in the U.S. “The overall healthcare costs for MS patients increased a lot…

The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on ongoing trials of evobrutinib, Merck KGaA’s experimental BTK inhibitor for relapsing forms of multiple sclerosis (MS). The decision was based on two cases of patients in Phase 3 clinical trials of evobrutinib who were…

Cariloop has teamed up with Walgreens to provide support services at select neurology-specialty pharmacies to people with multiple sclerosis (MS) and their caregivers. Through its caregiver platform, Cariloop offers services such as professional counseling and cloud-based tools to help families manage challenges and plan for caregiving-associated activities.

Training of the pelvic muscles, provided alongside lifestyle advice via telerehabilitation — tailored exercise instruction delivered via an online video call — significantly reduced urinary symptoms in women with multiple sclerosis (MS), a controlled study showed. The use of pelvic floor muscle training or PFMT, which are exercises…

The Multiple Sclerosis Association of America (MSAA) is holding its ninth annual Improving Lives Benefit to spotlight inspirational members of the multiple sclerosis (MS) community. This year’s fundraisers feature an in-person reception in Philadelphia on May 3 and a “Together at Home” virtual reception on May 18,…

The benefits of Mavenclad (cladribine) were sustained for up to 15 years after its last treatment course in people with relapsing multiple sclerosis (MS), according to real-world data from the CLASSIC-MS study. More than half of those who received the oral therapy in the clinical trials that supported…

One year of treatment with Lemtrada (alemtuzumab) significantly improved cognitive abilities, particularly with processing speed, and eased depression in people with relapsing forms of multiple sclerosis (MS), a small real-world study reported. Most of the 39 patients (92%) evaluated after that treatment year showed either stable or improved…

OCH, a molecule designed to have beneficial effects on immune regulation in multiple sclerosis (MS), led to increases in regulatory immune cell subsets and immunomodulatory gene activity in healthy volunteers and MS patients. That’s according to data from a first-in-human study of the compound, which also found the immune…

EBViously announced that it has developed a candidate vaccine against the Epstein-Barr virus and plans to bring it into clinical trials starting in 2024. The company is a spinoff of Helmholtz Munich, part of a German government research network. It is led by scientists with expertise in EBV…

OCS-05, a neuroprotective treatment candidate being developed by Oculis for multiple sclerosis (MS) or other causes of optic nerve inflammation, demonstrated a favorable safety and pharmacological profile in healthy volunteers, according to Phase 1 trial data. A Phase 2 trial (NCT04762017), called ACUITY, is now evaluating OCS-05’s…

Early treatment with Mavenclad (cladribine) or monoclonal antibodies is more likely to control symptoms in people with highly active multiple sclerosis (MS), a study in Argentina suggests. Highly active disease usually is considered when frequent relapses occur and there is an increasing burden of brain magnetic resonance imaging…

The world’s first mega-trial is recruiting people in the U.K. with progressive forms of multiple sclerosis (MS) to investigate the effectiveness of several approved therapies — at the same time. Named Octopus for its various arms, the study, which is expected to enroll at least 1,200 participants over…

Women with multiple sclerosis (MS) may have a higher risk of giving birth to premature or smaller babies, but it’s unclear if using MS medications during pregnancy has an effect on the baby’s health, according to a systematic review. The long-term health outcomes of children whose mothers have…